Figure 4.
Figure 4. CDD gene transfer increases granulocyte and thrombocyte nadir counts following gemcitabine application. Nadir levels of peripheral blood granulocyte (A) and thrombocyte (B) counts (mean ± SEM; n = 3-6 animals) following gemcitabine treatment administered at 2 × 250 mg/kg (G1, G2: n = 3 each) or 3 × 250 mg/kg (G1; G2: n = 3 each; administered intraperitoneally on consecutive days) are given. Data summarize 2 independent experiments. */** denotes significant differences (P < .05/.01) by Student t test.

CDD gene transfer increases granulocyte and thrombocyte nadir counts following gemcitabine application. Nadir levels of peripheral blood granulocyte (A) and thrombocyte (B) counts (mean ± SEM; n = 3-6 animals) following gemcitabine treatment administered at 2 × 250 mg/kg (G1, G2: n = 3 each) or 3 × 250 mg/kg (G1; G2: n = 3 each; administered intraperitoneally on consecutive days) are given. Data summarize 2 independent experiments. */** denotes significant differences (P < .05/.01) by Student t test.

Close Modal

or Create an Account

Close Modal
Close Modal